Pretty not long ago, preliminary results from a 3rd trial evaluating ibrutinib compared to observation had been introduced.a hundred and five Individuals obtaining ibrutinib experienced a longer event-no cost survival, but no Total survival edge, Even though the results were even now immature. Moreover, Whilst extreme adverse functions premiums end